Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Ziyan Chen, Yue Cheng, David DeRemer & Vakaramoko Diaby. (2021) Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 21:5, pages 923-941.
Read now
Read now
M. C. Cheung, A. Prica, J. Graczyk, R. Buckstein & K. K. W. Chan. (2016) Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis. Leukemia & Lymphoma 57:8, pages 1865-1875.
Read now
Read now
Natalia Olchanski, Yue Zhong, Joshua T. Cohen, Cayla Saret, Mohan Bala & Peter J. Neumann. (2015) The peculiar economics of life-extending therapies: a review of costing methods in health economic evaluations in oncology. Expert Review of Pharmacoeconomics & Outcomes Research 15:6, pages 931-940.
Read now
Read now
Karissa M Johnston, Corneliu Bolbocean, Joseph Connors & Stuart Peacock. (2012) Cost–effectiveness of rituximab in follicular lymphoma. Expert Review of Pharmacoeconomics & Outcomes Research 12:5, pages 569-577.
Read now
Read now
Chadi Nabhan, Sonali M. Smith & Brad S. Kahl. (2012) Maintenance rituximab in follicular non-Hodgkin lymphoma: facts and controversies. Leukemia & Lymphoma 53:5, pages 770-778.
Read now
Read now
Firas Badin & John Hayslip. (2010) Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness. ClinicoEconomics and Outcomes Research 2, pages 37-45.
Read now
Read now
Articles from other publishers (28)
Vasiliki Iliadou & Kostas Athanasakis. (2023) Sensitivity Analysis in Economic Evaluations of Immuno-Oncology Drugs: A Systematic Literature Review. Value in Health Regional Issues 37, pages 23-32.
Crossref
Crossref
Béranger Lueza, Anne Aupérin, Charlotte Rigaud, Thomas G. Gross, Marta Pillon, Rafael F. Delgado, Anne Uyttebroeck, G. A. Amos Burke, József Zsíros, Monika Csóka, Mathieu Simonin, Catherine Patte, Véronique Minard-Colin & Julia Bonastre. (2023) Cost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin’s lymphoma. The European Journal of Health Economics.
Crossref
Crossref
Nathan Fowler, Guifang Chen, Stephen Lim, Stephanie Manson, Qiufei Ma & Frank Li. (2023) reatment Patterns and Health Care Costs in Commercially Insured Patients with Follicular Lymphoma. Journal of Health Economics and Outcomes Research, pages 148-157.
Crossref
Crossref
Andrea C. Lo, Lyndon P. James, Anca Prica, Adam Raymakers, Stuart Peacock, Melody Qu, Alex V. Louie, Kerry J. Savage, Laurie H. Sehn, David Hodgson, Joanna C. Yang, Hans T.T. Eich, Andrew Wirth & M.G. Myriam Hunink. (2022) PET-Based Staging Is Cost-Effective in Early-Stage Follicular Lymphoma. Journal of Nuclear Medicine 63:4, pages 543-548.
Crossref
Crossref
Neerav Monga, Jamie Garside, Binu Gurung, Joan Quigley, Peter O’Donovan, Christoph Tapprich, Loretta Nastoupil, Catherine Thieblemont & Christina Loefgren. (2020) Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews. PharmacoEconomics - Open 4:4, pages 575-591.
Crossref
Crossref
Dominik Golicki, Katarzyna Jaśkowiak, Alicja Wójcik, Katarzyna Młyńczak, Iwona Dobrowolska, Andżelika Gawrońska, Grzegorz Basak, Emilian Snarski, Malwina Hołownia-Voloskova, Michał Jakubczyk & Maciej Niewada. (2020) EQ-5D–Derived Health State Utility Values in Hematologic Malignancies: A Catalog of 796 Utilities Based on a Systematic Review. Value in Health 23:7, pages 953-968.
Crossref
Crossref
Han-I Wang, Eve Roman, Simon Crouch, Eline Aas, Cathy Burton, Russell Patmore & Alexandra Smith. (2018) A Generic Model for Follicular Lymphoma: Predicting Cost, Life Expectancy, and Quality-Adjusted-Life-Year Using UK Population–Based Observational Data. Value in Health 21:10, pages 1176-1185.
Crossref
Crossref
Lu Zhang, Michele Ghielmini, Bruce D. Cheson & Chaitra Ujjani. (2017) Pros and cons of rituximab maintenance in follicular lymphoma. Cancer Treatment Reviews 58, pages 34-40.
Crossref
Crossref
Karen Lien, Matthew C. Cheung & Kelvin K.W. Chan. (2016) Adjusting for Drug Wastage in Economic Evaluations of New Therapies for Hematologic Malignancies: A Systematic Review. Journal of Oncology Practice 12:4, pages e369-e379.
Crossref
Crossref
Noemi Muszbek, Ananth Kadambi, Tereza Lanitis, Anthony J. Hatswell, Dilip Patel, Lixia Wang, Jack W. Singer & Ruth Pettengell. (2016) The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkin’s Lymphoma. Clinical Therapeutics 38:3, pages 503-515.
Crossref
Crossref
Jagpreet Chhatwal, Michael Mathisen & Hagop Kantarjian. (2015) Are high drug prices for hematologic malignancies justified? A critical analysis. Cancer 121:19, pages 3372-3379.
Crossref
Crossref
Anca Prica, Kelvin Chan & Matthew Cheung. (2015) Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis. Cancer 121:15, pages 2637-2645.
Crossref
Crossref
Hedwig M. Blommestein, Margreet G. Franken & Carin A. Uyl-de Groot. (2015) A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry. PharmacoEconomics 33:6, pages 551-560.
Crossref
Crossref
Hedwig M. Blommestein, Djamila E. Issa, Marjolein Pompen, Gerhard Ten Hoor, Mels Hogendoorn, Peter Joosten, Sonja Zweegman, Peter C. Huijgens & Carin A. Uyl-de Groot. (2014) Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study. European Journal of Haematology 92:5, pages 398-406.
Crossref
Crossref
Erkki J Soini, Miina Leussu & Taru Hallinen. (2013) Administration costs of intravenous biologic drugs for rheumatoid arthritis. SpringerPlus 2:1.
Crossref
Crossref
Amruth R. Palla & Mehdi Hamadani. (2012) Rituximab maintenance versus retreatment in follicular lymphoma. Hematological Oncology 31:4, pages 171-178.
Crossref
Crossref
Jean Yared, Amy Kimball, Maria R. Baer, Huzefa Bahrain & Michael Auerbach. (2013) Rituximab Maintenance Therapy Until Progression After Rituximab and Chemotherapy Induction in Patients With Follicular Lymphoma. Clinical Lymphoma Myeloma and Leukemia 13:3, pages 253-257.
Crossref
Crossref
Pier Luigi Zinzani, Monia Marchetti, Atto Billio, Giovanni Barosi, Angelo Michele Carella, Mario Lazzarino, Maurizio Martelli, Alessandro Rambaldi, Luigi Rigacci, Corrado Tarella, Umberto Vitolo & Sante Tura. (2013)
SIE
,
SIES
,
GITMO
revised guidelines for the management of follicular lymphoma
. American Journal of Hematology 88:3, pages 185-192.
Crossref
Crossref
Fay J. Hlubocky, Kimberly Webster, John Cashy, Jennifer Beaumont & David Cella. (2013) The Development and Validation of a Measure of Health-Related Quality of Life for Non-Hodgkin’s Lymphoma: The Functional Assessment of Cancer Therapy—Lymphoma (FACT-Lym). Lymphoma 2013, pages 1-9.
Crossref
Crossref
Julian F. Guest, Monica Panca, Erikas Sladkevicius, Nicholas Gough & Mark Linch. (2013) Cost Effectiveness of First-Line Treatment with Doxorubicin/Ifosfamide Compared to Trabectedin Monotherapy in the Management of Advanced Soft Tissue Sarcoma in Italy, Spain, and Sweden. Sarcoma 2013, pages 1-19.
Crossref
Crossref
Philipp W.P. Auweiler, Dirk Müller, Stephanie Stock & Andreas Gerber. (2012) Cost Effectiveness of Rituximab for Non-Hodgkinʼs Lymphoma. PharmacoEconomics 30:7, pages 537-549.
Crossref
Crossref
Erkki J. Soini, Janne A. Martikainen, Ville Vihervaara, Kim Mustonen & Tapio Nousiainen. (2012) Economic Evaluation of Sequential Treatments for Follicular Non-Hodgkin Lymphoma. Clinical Therapeutics 34:4, pages 915-925.e2.
Crossref
Crossref
Liat Vidal, Anat Gafter-Gvili, Gilles Salles, Martin H. Dreyling, Michele Ghielmini, Shu-Fang Hsu Schmitz, Ruth Pettengell, Mathias Witzens-Harig & Ofer Shpilberg. (2011) Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: An Updated Systematic Review and Meta-analysis of Randomized Trials. JNCI: Journal of the National Cancer Institute 103:23, pages 1799-1806.
Crossref
Crossref
E.J.O. Soini, J.A. Martikainen & T. Nousiainen. (2011) Treatment of follicular non-Hodgkin's lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up. Annals of Oncology 22:5, pages 1189-1197.
Crossref
Crossref
Gillian M. Keating. (2011) Spotlight on Rituximab in Chronic Lymphocytic Leukemia, Low-Grade or Follicular Lymphoma, and Diffuse Large B-Cell Lymphoma†. BioDrugs 25:1, pages 55-61.
Crossref
Crossref
Gillian M. Keating. (2010) Rituximab. Drugs 70:11, pages 1445-1476.
Crossref
Crossref
Joshua A. Ray, Emma Carr, Gavin Lewis & Robert Marcus. (2010) An Evaluation of the Cost-Effectiveness of Rituximab in Combination with Chemotherapy for the First-Line Treatment of Follicular Non-Hodgkin's Lymphoma in the UK. Value in Health 13:4, pages 346-357.
Crossref
Crossref
Eric Deconinck, Houda Miadi-Fargier, Claude Le Pen & Pauline Brice. (2010) Cost Effectiveness of Rituximab Maintenance Therapy in Follicular Lymphoma. PharmacoEconomics 28:1, pages 35-46.
Crossref
Crossref